Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 2Primary Myelofibrosis 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 4Fluorouracil 4Bevacizumab 4fludarabine 3aldesleukin 3Radiosurgery 3Gemcitabine 3Endoscopic Mucosal Resection 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3Surveys and Questionnaires 2Sunitinib 2Pemetrexed 2Oxaliplatin 2Leucovorin 2IDRX-42 2Folfox protocol 2trastuzumab deruxtecan 1tislelizumab 1sodium thiosulfate 1sodium propionate 1semaglutide 1repotrectinib 1plecanatide 1pembrolizumab 1patritumab deruxtecan 1palbociclib 1linaclotide 1isosorbide-5-mononitrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × canakinumab × 90 days × Clear all
NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡